Functional characterization of epithelial ovarian cancer histotypes by drug target based protein signaling activation mapping: Implications for personalized cancer therapy

Proteomics

Volumn 15, Issue 2-3, 2015, Pages 365-373

  Sereni, Maria Isabella ^a,b   Baldelli, Elisa ^a,b,c   Gambara, Guido ^a   Deng, Jianghong ^a   Zanotti, Laura ^b   Bandiera, Elisabetta ^b   Bignotti, Eliana ^b   Ragnoli, Monica ^b   Tognon, Germana ^b   Ravaggi, Antonella ^b   Meani, Francesco ^a   Memo, Maurizio ^b   Angioli, Roberto ^d   Liotta, Lance A ^a   Pecorelli, Sergio L ^b   Petricoin, Emanuel ^a   Pierobon, Mariaelena ^a  

^a GEORGE MASON UNIVERSITY   (United States)

^b UNIVERSITY OF BRESCIA   (Italy)

^c SANTA MARIA DELLA MISERICORDIA HOSPITAL   (Italy)

^d UNIVERSITY CAMPUS BIO MEDICO   (Italy)

Author keywords

Clear cell carcinoma; HER2 ErbB2; Ovarian cancer; Phosphorylation; Protein arrays

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; PROTEIN; PROTEIN KINASE SYK; PROTEIN TYROSINE PHOSPHATASE SHP 2; EGFR PROTEIN, HUMAN; PROTEIN TYROSINE KINASE; SIGNAL PEPTIDE;

ADULT; AGED; ANALYSIS OF VARIANCE; ARTICLE; CANCER CLASSIFICATION; CANCER STAGING; CANCER SURVIVAL; CANCER THERAPY; CONTROLLED STUDY; ENZYME ACTIVATION; FEMALE; HISTOLOGY; HUMAN; HUMAN TISSUE; LASER CAPTURE MICRODISSECTION; MAJOR CLINICAL STUDY; MIDDLE AGED; OVARY CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN MICROARRAY; SIGNAL TRANSDUCTION; METABOLISM; MOLECULARLY TARGETED THERAPY; NEOPLASM; OVARY; OVARY TUMOR; PATHOLOGY; PERSONALIZED MEDICINE; PROTEIN PROTEIN INTERACTION; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; HUMANS; INDIVIDUALIZED MEDICINE; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MIDDLE AGED; MOLECULAR TARGETED THERAPY; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; OVARY; PROTEIN ARRAY ANALYSIS; PROTEIN INTERACTION MAPS; PROTEIN TYROSINE PHOSPHATASE, NON-RECEPTOR TYPE 11; PROTEIN-TYROSINE KINASES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; SIGNAL TRANSDUCTION; YOUNG ADULT;

EID: 84921266358     PISSN: 16159853     EISSN: 16159861     Source Type: Journal    
DOI: 10.1002/pmic.201400214     Document Type: Article

References (36)

1. Ferlay, J., Shin, H. R., Bray, F., Forman, D. et al., Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int. J. Cancer 2010, 127, 2893-2917.
2. Lee, K. R., Tavassoli, F. A., Prat, J., Dietel, M. et al., Surface epithelial stromal tumours: Tumours of the ovary and peritoneum. in: Tavassoli, F. A., Devilee P. (Eds.), World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of the Breast and Female Genital Organs, IARC Press, Lyon 2003, pp. 117-145.
3. Vaughan, S., Coward, J. I., Bast, R. C., Berchuck, A. et al., Rethinking ovarian cancer: recommendations for improving outcomes. Nat. Rev. Cancer 2011, 11, 719-725.
4. Markman, M., Current standards of care for chemotherapy of optimally cytoreduced advanced epithelial ovarian cancer. Gynecol. Oncol. 2013, 131, 241-245.
5. Eskander, R. N., Tewari, K. S., Incorporation of anti-angiogenesis therapy in the management of advanced ovarian carcinoma-mechanistics, review of phase III randomized clinical trials, and regulatory implications. Gynecol. Oncol. 2014, 132, 496-505.
6. Davidson, B. A., Secord, A. A., Profile of pazopanib and its potential in the treatment of epithelial ovarian cancer. Int. J. Womens Health 2014, 6, 289-300.
7. Smolle, E., Taucher, V., Petru, E., Haybaeck, J., Targeted treatment of ovarian cancer-the multiple-kinase-inhibitor sorafenib as a potential option. Anticancer Res. 2014, 34, 1519-1530.
8. Liu, J. F., Konstantinopoulos, P. A., Matulonis, U. A., PARP inhibitors in ovarian cancer: current status and future promise. Gynecol. Oncol. 2014, 133, 362-369.
9. Sieh, W., Köbel, M., Longacre, T. A., Bowtell, D. D. et al., Hormone-receptor expression and ovarian cancer survival: an Ovarian Tumor Tissue Analysis consortium study. Lancet Oncol. 2013, 14, 853-862.
10. Wiegand, K. C., Shah, S. P., Al-Agha, O. M., Zhao, Y. et al., ARID1A mutations in endometriosis-associated ovarian carcinomas. N. Engl. J. Med. 2010, 363, 1532-1543.
11. Vergote, I. B., Jimeno, A., Joly, F., Katsaros, D. et al., Randomized phase III study of erlotinib versus observation in patients with no evidence of disease progression after first-line platin-based chemotherapy for ovarian carcinoma: a European Organisation for Research and Treatment of Cancer-Gynaecological Cancer Group, and Gynecologic Cancer Intergroup study. J. Clin. Oncol. 2014, 32, 320-326.
12. Espina, V., Edmiston, K. H., Heiby, M., Pierobon, M. et al., A portrait of tissue phosphoprotein stability in the clinical tissue procurement process. Mol. Cell Proteomics 2008, 7, 1998-2018.
13. Espina, V., Mueller, C., Edmiston, K., Sciro, M. et al., Tissue is alive: new technologies are needed to address the problems of protein biomarker pre-analytical variability. Proteomics Clin. Appl. 2009, 3, 874-882.
14. Espina, V., Edmiston, K. H., Heiby, M., Pierobon, M. et al., A portrait of tissue phosphoprotein stability in the clinical tissue procurement process. Mol. Cell Proteomics 2008, 7, 1998-2018.
15. Wulfkuhle, J. D., Speer, R., Pierobon, M., Laird, J. et al., Multiplexed cell signaling analysis of human breast cancer applications for personalized therapy. J. Proteome Res. 2008, 7, 1508-1517.
16. Yan, M., Parker, B. A., Schwab, R., Kurzrock, R., HER2 aberrations in cancer: implications for therapy. Cancer Treat Rev. 2014, 40, 770-780.
17. Rembielak, A. I., Jain, P., Jackson, A. S., Green, M. M. et al., Phase II trial of cetuximab and conformal radiotherapy only in locally advanced pancreatic cancer with concurrent tissue sampling feasibility study. Transl. Oncol. 2014, 7, 55-64.
18. Havaleshko, D. M., Smith, S. C., Cho, H., Cheon, S. et al., Comparison of global versus epidermal growth factor receptor pathway profiling for prediction of lapatinib sensitivity in bladder cancer. Neoplasia 2009, 11, 1185-1193.
19. Rapkiewicz, A., Espina, V., Zujewski, J. A., Lebowitz, P. F. et al., The needle in the haystack: application of breast fine-needle aspirate samples to quantitative protein microarray technology. Cancer 2007, 111, 173-184.
20. Wiegand, K. C., Hennessy, B. T., Leung, S., Wang, Y. et al., A functional proteogenomic analysis of endometrioid and clear cell carcinomas using reverse phase protein array and mutation analysis: protein expression is histotype-specific and loss of ARID1A/BAF250a is associated with AKT phosphorylation. BMC Cancer 2014, 14, 120-131.
21. Tan, D. S., Iravani, M., McCluggage, W. G., Lambros, M. B. et al., Genomic analysis reveals the molecular heterogeneity of ovarian clear cell carcinomas. Clin. Cancer Res. 2011, 17, 1521-1534.
22. Tan, T. Z., Miow, Q. H., Huang, R. Y., Wong, M. K. et al., Functional genomics identifies five distinct molecular subtypes with clinical relevance and pathways for growth control in epithelial ovarian cancer. EMBO Mol. Med. 2013, 5, 983-998.
23. Stany, M. P., Vathipadiekal, V., Ozbun, L., Stone, R. L. et al., Identification of novel therapeutic targets in microdissected clear cell ovarian cancers. PLoS One 2011, 6, e21121.
24. Network, C. G. A. R., Integrated genomic analyses of ovarian carcinoma. Nature 2011, 474, 609-615.
25. Kasimir-Bauer, S., Hoffmann, O., Wallwiener, D., Kimmig, R., Fehm, T., Expression of stem cell and epithelial-mesenchymal transition markers in primary breast cancer patients with circulating tumor cells. Breast Cancer Res. 2012, 14, R15.
26. Rauh-Hain, J. A., Davis, M., Clemmer, J., Clark, R. M. et al., Prognostic determinants in patients with uterine and ovarian clear cell carcinoma: a SEER analysis. Gynecol. Oncol. 2013, 131, 404-409.
27. del Carmen, M. G., Birrer, M., Schorge, J. O., Clear cell carcinoma of the ovary: a review of the literature. Gynecol. Oncol. 2012, 126, 481-490.
28. Berchuck, A., Rodriguez, G. C., Kamel, A., Dodge, R. K. et al., Epidermal growth factor receptor expression in normal ovarian epithelium and ovarian cancer. I. Correlation of receptor expression with prognostic factors in patients with ovarian cancer. Am. J. Obstet. Gynecol. 1991, 164, 669-674.
29. Fischer-Colbrie, J., Witt, A., Heinzl, H., Speiser, P. et al., EGFR and steroid receptors in ovarian carcinoma: comparison with prognostic parameters and outcome of patients. Anticancer Res. 1997, 17, 613-619.
30. Scambia, G., Benedetti-Panici, P., Ferrandina, G., Distefano, M. et al., Epidermal growth factor, oestrogen and progesterone receptor expression in primary ovarian cancer: correlation with clinical outcome and response to chemotherapy. Br. J. Cancer 1995, 72, 361-366.
31. Li, S., Hsu, D. D., Wang, H., Feng, G. S., Dual faces of SH2-containing protein-tyrosine phosphatase Shp2/PTPN11 in tumorigenesis. Front Med. 2012, 6, 275-279.
32. Xu, E., Schwab, M., Marette, A., Role of protein tyrosine phosphatases in the modulation of insulin signaling and their implication in the pathogenesis of obesity-linked insulin resistance. Rev. Endocr. Metab. Disord. 2014, 15, 79-97.
33. Olsen, C. M., Nagle, C. M., Whiteman, D. C., Purdie, D. M. et al., Body size and risk of epithelial ovarian and related cancers: a population-based case-control study. Int. J. Cancer 2008, 123, 450-456.
34. Silvestri, A., Colombatti, A., Calvert, V. S., Deng, J. et al., Protein pathway biomarker analysis of human cancer reveals requirement for upfront cellular-enrichment processing. Lab. Invest. 2010, 90, 787-796.
35. Mueller, C., de Carvalho, A. C., Mikkelsen, T., Lehman, N. L. et al., Glioblastoma cell enrichment is critical for analysis of phosphorylated drug targets and proteomic-genomic correlations. Cancer Res. 2014, 74, 818-828.
36. Wulfkuhle, J. D., Berg, D., Wolff, C., Langer, R. et al., Molecular analysis of HER2 signaling in human breast cancer by functional protein pathway activation mapping. Clin. Cancer Res. 2012, 18, 6426-6435.